Trial reportEuropean journal of heart failure2019
Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-IT predictive model and risk score.
Trial report in European journal of heart failure, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01685840 (Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.), which is not on this map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Effects of Benzodiazepines on Heart Failure Outcomes and Adverse Events: A Systematic Review and Meta-Analysis.Cardiovascular toxicology · 2026Pooled it
- SESC heart failure · 2024Trial
- The Prognostic Significance of the Pan-Immune-Inflammation Value in Patients with Heart Failure with Reduced Ejection Fraction.Diagnostics (Basel, Switzerland) · 2025Article
- Machine learning-based model for worsening heart failure risk in Chinese chronic heart failure patients.ESC heart failure · 2025Article
- Effect of different diastolic blood pressure levels on the prognosis of patients with heart failure after acute myocardial infarction.Frontiers in cardiovascular medicine · 2025Article
- AI hybrid survival assessment for advanced heart failure patients with renal dysfunction.Nature communications · 2024Article
- Article
- Prognostic Role of Ultrasound Diagnostic Methods in Patients with Acute Decompensated Heart Failure.Oman medical journal · 2024Article
- Prognostic Impact of Repeated NT-proBNP Measurements in Patients With Heart Failure With Reduced Ejection Fraction.JACC. Heart failure · 2024Article
- Efficacy and safety of sacubitril/valsartan after six months in patients with heart failure with reduced ejection fraction and asymptomatic hypotension.Journal of geriatric cardiology : JGC · 2023Article
- Heart Failure with Reduced Ejection Fraction: The Role of Cardiovascular and Lung Ultrasound beyond Ejection Fraction.Diagnostics (Basel, Switzerland) · 2023Review
- Prognostic Role of Metabolic Exercise Testing in Heart Failure.Journal of clinical medicine · 2023Review
- The Role of Congestion Biomarkers in Heart Failure with Reduced Ejection Fraction.Journal of clinical medicine · 2023Review
- Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial.European heart journal · 2022Article
- SGLT2 Inhibitors Improve Cardiac Failure by Reducing Whole-Body Oxygen Demand: A Hypothesis.Clinical drug investigation · 2022Review
- Data-driven identification of heart failure disease states and progression pathways using electronic health records.Scientific reports · 2022Article
- Decongestion Models and Metrics in Acute Heart Failure: ESCAPE Data in the Age of the Implantable Cardiac Pressure Monitor.Texas Heart Institute journal · 2022Article
- Liver stiffness for predicting adverse cardiac events in chinese patients with heart failure: a two-year prospective study.BMC cardiovascular disorders · 2022Article
- The influence of comorbidities on achieving an N-terminal pro-b-type natriuretic peptide target: a secondary analysis of the GUIDE-IT trial.ESC heart failure · 2022Article
- C4d as a Screening Tool and an Independent Predictor of Clinical Outcomes in Lupus Nephritis and IgA Nephropathy.Frontiers in medicine · 2022Article
Corrections and comments
- Commented on by
Authors and funding
15 authors at 10 institutions in 2 countries.
Funding
Abstract
backgroundMost heart failure (HF) risk scores have been derived from cohorts of stable HF patients and may not incorporate up to date treatment regimens or deep phenotype characterization that change baseline risk over the short- and long-term follow-up period. We undertook the current analysis of participants in the GUIDE-IT (Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment) trial to address these limitations. METHODS AND
resultsThe GUIDE-IT study randomized 894 high-risk patients with HF and reduced ejection fraction (≤ 40%) to biomarker-guided treatment strategy vs. usual care. We performed risk modelling using Cox proportional hazards models and analysed the relationship between 35 baseline clinical factors and the primary composite endpoint of cardiovascular (CV) death or HF hospitalization, the secondary endpoint of all-cause mortality, and the exploratory endpoint of 90-day HF hospitalization or death. Prognostic relationships for continuous variables were examined and key predictors were identified using a backward variable selection process. Predictive models and risk scores were developed. Over a median follow-up of 15 months, the cumulative number of HF hospitalizations and CV deaths was 328 out of 894 patients (Kaplan-Meier event rate 34.5% at 12 months). Frequency of all-cause deaths was 143 out of 894 patients (Kaplan-Meier event rate 12.2% at 12 months). Outcomes for the primary and secondary endpoints between strategy arms of the study were similar. The most important predictor that was present in all three models was the baseline natriuretic peptide level. Hispanic ethnicity, low sodium and high heart rate were present in two of the three models. Other important predictors included the presence or absence of a device, New York Heart Association class, HF duration, black race, co-morbidities (sleep apnoea, elevated creatinine, ischaemic heart disease), low blood pressure, and a high congestion score.
conclusionRisk models using readily available clinical information are able to accurately predict short- and long-term CV events and may be useful in optimizing care and enriching patients for clinical trials. CLINICAL
trial registrationClinicalTrials.gov ID number NCT01685840.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.